LEXXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:32):

Stats
本日の出来高	55 344.00
平均出来高	495 362
時価総額	30.20M
EPS	$0 ( 2024-04-12 )
次の収益日	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.90
ATR14	$0.0160 (0.66%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Cabatuan Nelson	Sell	200 000	Stock Options
2023-10-26	Carle Vanessa	Buy	12 500	Stock Options
2023-10-26	Docherty John Martin	Buy	30 000	Stock Options
2023-10-26	Bunka Christopher	Buy	30 000	Stock Options
2023-07-25	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
-25.05
Last 99 transactions
Buy: 4 974 810 \| Sell: 2 651 735

ボリューム相関

長: -0.06 (neutral)

短: 0.48 (neutral)

Signal:(56.316) Neutral

Lexaria Bioscience Corp. 相関

10 最も正の相関
RMRM	0.854
AKU	0.828
GAINL	0.828
LPLA	0.824
UNB	0.822
LMST	0.821
OCFC	0.809
SFBC	0.807
EFSC	0.807
LBAI	0.806

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Lexaria Bioscience Corp. 相関 - 通貨/商品

0.77
( moderate )

0.73
( moderate )

0.00
( neutral )

0.78
( moderate )

-0.61
( weak negative )

-0.83
( strong negative )

Lexaria Bioscience Corp. 財務諸表

Annual	2023
収益:	$226 208
総利益:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2023
収益:	$226 208
総利益:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2022
収益:	$255 397
総利益:	$183 556 (71.87 %)
EPS:	$-1.240

FY	2021
収益:	$722 738
総利益:	$547 392 (75.74 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.